The lack of effective treatments for GBM urges the need for pre-clinical testing of auranofin and L-BSO combination in orthotopic EGFR-positive GBM model in vivo to translate our findings and repurpose relatively well-tolerated drugs in future clinical trials. The gene discussed is EGFR; the disease is glioblastoma.